苯丁酸甘油酯（glyceryl phenylbutyrate, GPB）是治疗鸟氨酸氨甲酰基转移酶缺乏症（ornithine transcarbamylase deficiency, OTCD）的长期管理药物，可有效控制高氨血症，但国内使用该药的经验匮乏。该文回顾性分析上海交通大学医学院附属上海儿童医学中心1例诊断为OTCD的患儿资料，并进行相关文献复习。该患儿确诊后使用GPB治疗，随后进行疗效随访和药学监测。患儿，男，6岁6个月，语言发育差，不听指令，脾气暴躁并伴有攻击性行为。监测血氨最高327 μmol/L；尿有机酸分析提示尿嘧啶水平升高；头颅磁共振成像示双侧大脑半球广泛异常信号；基因检测发现OTC基因新生突变（c.241T>C，p.S81P）。予以GPB治疗后1、2、3个月左右的血氨分别为43、80、56 μmol/L。患儿治疗期间血氨控制良好，未见与药物相关的不良反应，发育落后情况较前改善，可听指令，脾气好转，无攻击性行为。
Abstract
Glyceryl phenylbutyrate (GPB) serves as a long-term management medication for Ornithine transcarbamylase deficiency (OTCD), effectively controlling hyperammonemia, but there is a lack of experience in using this medicine in China. This article retrospectively analyzes the case of a child diagnosed with OTCD at Shanghai Children's Medical Center, Shanghai Jiao Tong University School of Medicine, including a review of related literature. After diagnosis, the patient was treated with GPB, followed by efficacy follow-up and pharmacological monitoring. The 6-year and 6-month-old male patient exhibited poor speech development, disobedience, temper tantrums, and aggressive behavior. Blood ammonia levels peaked at 327 μmol/L; urine organic acid analysis indicated elevated uracil levels; cranial MRI showed extensive abnormal signals in both cerebral hemispheres. Genetic testing revealed de novo mutation in the OTC gene (c.241T>C, p.S81P). Blood ammonia levels were approximately 43, 80, and 56 μmol/L at 1, 2, and 3 months after starting GPB treatment, respectively. During treatment, blood ammonia was well-controlled without drug-related adverse effects. The patient showed improvement in developmental delays, obedience, temperament, and absence of aggressive behavior.
关键词
苯丁酸甘油酯 /
鸟氨酸氨甲酰基转移酶缺乏症 /
尿素循环障碍 /
高氨血症 /
药学监测 /
儿童
Key words
Glyceryl phenylbutyrate /
Ornithine aminotransferase deficiency /
Urea cycle disorder /
Hyperammonemia /
Pharmacological monitoring /
Child
{{custom_sec.title}}
{{custom_sec.title}}
{{custom_sec.content}}
参考文献
1 Summar ML, Koelker S, Freedenberg D, et al. The incidence of urea cycle disorders[J]. Mol Genet Metab, 2013, 110(1-2): 179-180. PMID: 23972786. PMCID: PMC4364413. DOI: 10.1016/j.ymgme.2013.07.008.
2 Matsumoto S, H?berle J, Kido J, et al. Urea cycle disorders: update[J]. J Hum Genet, 2019, 64(9): 833-847. PMID: 31110235. DOI: 10.1038/s10038-019-0614-4.
3 Redant S, Empain A, Mugisha A, et al. Management of late onset urea cycle disorders: a remaining challenge for the intensivist?[J]. Ann Intensive Care, 2021, 11(1): 2. PMID: 33409766. PMCID: PMC7788146. DOI: 10.1186/s13613-020-00797-y.
4 杨臻峥. 用于治疗尿素循环障碍的药物苯丁酸甘油酯[J]. 药学进展, 2013, 37(2): 96-97. DOI: 10.3969/j.issn.1001-5094.2013.02.013.
5 Yeo M, Rehsi P, Dorman M, et al. Clinical experience with glycerol phenylbutyrate in 20 patients with urea cycle disorders at a UK paediatric centre[J]. JIMD Rep, 2023, 64(5): 317-326. PMID: 37701329. PMCID: PMC10494499. DOI: 10.1002/jmd2.12386.
6 Longo N, Diaz GA, Lichter-Konecki U, et al. Glycerol phenylbutyrate efficacy and safety from an open label study in pediatric patients under 2 months of age with urea cycle disorders[J]. Mol Genet Metab, 2021, 132(1): 19-26. PMID: 33388234. PMCID: PMC8655853. DOI: 10.1016/j.ymgme.2020.12.002.
7 Martín-Hernández E, Quijada-Fraile P, Correcher P, et al. Switching to glycerol phenylbutyrate in 48 patients with urea cycle disorders: clinical experience in Spain[J]. J Clin Med, 2022, 11(17): 5045. PMID: 36078975. PMCID: PMC9457033. DOI: 10.3390/jcm11175045.
8 Diaz GA, Schulze A, Longo N, et al. Long-term safety and efficacy of glycerol phenylbutyrate for the management of urea cycle disorder patients[J]. Mol Genet Metab, 2019, 127(4): 336-345. PMID: 31326288. DOI: 10.1016/j.ymgme.2019.07.004.
9 Berry SA, Lichter-Konecki U, Diaz GA, et al. Glycerol phenylbutyrate treatment in children with urea cycle disorders: pooled analysis of short and long-term ammonia control and outcomes[J]. Mol Genet Metab, 2014, 112(1): 17-24. PMID: 24630270. PMCID: PMC4382922. DOI: 10.1016/j.ymgme.2014.02.007.
10 Berry SA, Longo N, Diaz GA, et al. Safety and efficacy of glycerol phenylbutyrate for management of urea cycle disorders in patients aged 2 months to 2 years[J]. Mol Genet Metab, 2017, 122(3): 46-53. PMID: 28916119. DOI: 10.1016/j.ymgme.2017.09.002.
11 中国妇幼保健协会儿童疾病和保健分会遗传代谢学组. 鸟氨酸氨甲酰转移酶缺乏症诊治专家共识[J]. 浙江大学学报（医学版）, 2020, 49(5): 539-547. PMID: 33210478. PMCID: PMC8800749. DOI: 10.3785/j.issn.1008-9292.2020.04.11.
12 Posset R, Gropman AL, Nagamani SCS, et al. Impact of diagnosis and therapy on cognitive function in urea cycle disorders[J]. Ann Neurol, 2019, 86(1): 116-128. PMID: 31018246. PMCID: PMC6692656. DOI: 10.1002/ana.25492.
13 H?berle J, Burlina A, Chakrapani A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders: first revision[J]. J Inherit Metab Dis, 2019, 42(6): 1192-1230. PMID: 30982989. DOI: 10.1002/jimd.12100.
基金
上海市“科技创新行动计划”医学创新研究专项（20MC1920400）；浦东新区卫健委联合攻关项目（PW2021D-13）。
PDF(1786 KB)
